Company intelligence / Profile preview

Oncoceutics

Philadelphia, Pennsylvania, United Stateschimerix.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Oncoceutics developed ONC201, an orally active small molecule DRD2 antagonist with demonstrated safety and efficacy in early clinical trials for advanced cancers. The company completed a successful Phase I study in solid tumors and was focused on first approval for H3 K27M-mutant high-grade glioma before being acquired by Chimerix. Their compounds selectively target GPCRs to restore tumor suppressor pathways such as p53.

Therapeutic areas: Oncology
Modalities: Small moleculeImipridone (a class of small molecules)
Industry: Biotech

Partnerships

Not specifically listed; investors include Chimerix, Frontida Biopharm, Spring Mountain Capital, Musella Foundation for Brain Tumor Research & Information.

Beyond the preview

Go deeper on Oncoceutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncoceutics.

Explore the full profile